Azithromycin Treatment Increases Survival of High-Risk Corneal Allotransplants

Abstract

AZM is effective in prolonging survival of high-risk corneal allografts by an as yet undefined mechanism that does not seem to involve modulation of corneal neovascularization or allospecific T-cell priming.